Compare Comcast Corporation (CMCSA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Summit Therapeutics Inc — how do they compare? Comcast Corporation trades at $25.35 (market cap $91.02B), while Summit Therapeutics Inc trades at $15.21 (market cap $12.06B). The key difference: Comcast Corporation is far larger — about 7.5× Summit Therapeutics Inc's market cap, and Comcast Corporation pays a 5.15% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CMCSA | SMMT | |
|---|---|---|
Market Cap | $91.02B | $12.06B |
Sector | Media | Health |
52-Week High | $32.50 | $26.98 |
52-Week Low | $21.92 | $12.55 |
Enterprise Value | $173.74B | $11.39B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMCSA trades at $25.185, down slightly by 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The company shows strong fundamentals with a low P/E of 8.22, consistent earnings beats in recent quarters, and robust cash flow generation of $33.64 billion from operations in 2025. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff.
The outlook for CMCSA is positive, supported by attractive valuation, steady dividend payments, and growth in wireless and streaming. Key risks include competitive pressures in media and broadband, execution of the spinoff, and macroeconomic sensitivity. Analyst consensus is bullish with a $27.78 price target, implying potential upside from current levels.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
